FLASCO

Corporate Members

Diamond Elite

Diamond

Platinum

Gold

Silver



On February 15th FLASCO hosted a free “Living with Metastatic Breast Cancer” luncheon Patient Advocacy Program at the Capitol Building in Tallahassee. This educational program was for people who have this advanced type of cancer and their caregivers. The event featured speakers representing the Mayo Clinic Florida, Florida Cancer Specialists, Tallahassee Memorial Cancer Center, and the Florida Breast Cancer Foundation. The speakers discussed the disease itself, treatment options, patient advocacy, caring for the caregiver, and patient assistance programs. A question-and-answer session followed the formal presentations.

Celeste Phillip, MD, MPH, Florida Surgeon General and Secretary Florida Department of Health, joined us on behalf of Governor Scott, to present the Governor’s Proclamation declaring February 2017 as Metastatic Breast Cancer Awareness Month. Click here to read the Proclamation. We were pleased to also have Representative Lori Berman join the audience.

This event would not have been possible without the generous support of our sponsors and exhibitors. Thank you to our grant providers:Pfizer and Florida Breast Cancer Foundation, Meeting sponsor: NanoString Technologies, and Exhibitors: AstraZeneca and Insys.


Latest News

FDA Approves RITUXAN HYCELA for Subcutaneous Injection in Certain Blood Cancers

Posted June 23, 2017

The FDA approved RITUXAN HYCELA™ (rituximab and hyaluronidase human) for subcutaneous injection for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukemia (CLL). The Genentech press release including Important Safety Information...

FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation

Posted June 23, 2017

On June 22, 2017, the U.S. Food and Drug Administration granted regular approvals to dabrafenib and trametinib (TAFINLAR® and MEKINIST®, Novartis Pharmaceuticals Inc.) administered in combination for patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. These are the first FDA approvals specifically for treatment of...

Reflecting With Gratitude on Gifts From My Patients

Posted June 22, 2017

A massive, 2-pound box of assorted chocolates sat opened on the table in the physicians’ workroom, with various pieces missing. There was no key on the underside of the box lid to help identify the chocolate types, so choosing a piece was a bit of a gamble. The candy was a gift from a patient...

Luis Raez, MD, on Mutation Testing in NSCLC

Posted June 16, 2017

Transcript: Luis Raez, MD: Nowadays, it’s very interesting. We have changed the standard of care for molecular testing. There was no molecular testing 4 or 5 years ago. Now, every new patient with lung cancer, especially nonsquamous non–small cell lung cancer, needs next-generation sequencing testing, generally from the tissue. And there is a lot of...

Dr. Elizabeth Kent Joins Florida Cancer Specialists & Research Institute

Posted June 16, 2017

Brought to you by a 100% FLASCO Membership Partner Nation’s Largest Independent Oncology Group  Welcomes New Physician in Jacksonville / Fleming Island Fleming Island, FL – June 15, 2017. . . Florida Cancer Specialists & Research Institute (FCS), the leading community oncology/hematology practice in the state, is pleased to announce that Elizabeth C. Kent, MD...

Who’s Online

There are no users currently online